MYC regulates the antitumor immune response through CD47 and PD-L1
about
Multi-organ Mapping of Cancer RiskFAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC.Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1PBMC transcriptome profiles identifies potential candidate genes and functional networks controlling the innate and the adaptive immune response to PRRSV vaccine in Pietrain pigStrategies to Inhibit Myc and Their Clinical ApplicabilityA Self-Training Subspace Clustering Algorithm under Low-Rank Representation for Cancer Classification on Gene Expression Data.Different promoter affinities account for specificity in MYC-dependent gene regulation.Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunityWhat does PD-L1 positive or negative mean?The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.Emerging roles of p53 and other tumour-suppressor genes in immune regulationA CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancerTargeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.Roles of Wnt Target Genes in the Journey of Cancer Stem CellsEvasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancerMechanisms of Immune Tolerance in Leukemia and Lymphoma.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinomaMolecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapiesCancer Immunotherapy: Whence and Whither.Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity.Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.Mouse models in oncoimmunology.MGUS to myeloma: a mysterious gammopathy of underexplored significance.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.Innate immune signaling and regulation in cancer immunotherapy.BET Bromodomain Proteins as Cancer Therapeutic Targets.Tumour-associated macrophages as treatment targets in oncology.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.MYC: Master Regulator of Immune Privilege.Modeling and Targeting MYC Genes in Childhood Brain Tumors.The MYCN Protein in Health and Disease.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer.
P2860
Q26701396-7C306124-8CF8-4589-98D1-7179B959DEB6Q33789691-B3EE89F0-E65B-42B6-A9CA-AE74E5543D4CQ33802505-8F0A5B30-6A9E-437B-BDE2-C04E05B497D0Q33839204-5B4B2FD0-77F6-442B-BDE6-71F48D95AF60Q34048020-7BA3412E-2599-4922-A32D-E891BD1263C4Q36302374-EC861456-2EE0-4D1B-A128-0EE25350A529Q36303678-5C4BA0CA-3D8C-40AB-8717-D8BACEDEA343Q36397264-456BA768-782D-4235-9DEC-E6B5ADD39EEBQ37131368-E4B28AF8-720D-4715-96D3-5A947E7EED33Q37233276-BE1814F2-45BB-46EB-AB34-0B0F1135F237Q37313139-8FB5CCCC-47F6-4ABB-BF1F-0470DDBE07B3Q37500381-00D8A9C4-B7E6-4AB7-8C87-4E8A11AD711BQ37600827-E700CF5D-FF32-4197-AD02-92FC39E8203FQ37666015-FF54E3BD-F73E-483B-884E-02DC74227A71Q37739218-5AC8330B-AA44-4434-A809-790A0DA7D3EFQ38377528-64EEDCE3-E226-4B38-BDB5-FB0606D47BD1Q38557075-27842B11-A6DD-4A05-8070-095FDFE19D78Q38663576-A3E04CA1-D8E2-4C2F-915A-7E80CE0804FBQ38683034-8A210ACE-C583-4FFC-A6F8-004F02BB70F2Q38719539-22F621F9-5EB6-46A7-A020-7651E08D8A18Q38736110-03FDC596-E5C0-4E51-B324-5DDB3C85A6F7Q38737924-0DDB3B42-59BA-401A-8694-6E9940AFDD0DQ38815767-33249ABE-3363-4FA2-8F3D-E0974B98557BQ38875037-A18342FA-3C68-48AF-841D-F957D1159582Q38930113-B7684ED2-CD8C-4E8E-BCBC-FD5E0436BA8CQ38968582-1F63997C-DFCF-4526-A31B-E5CA8DC9C96DQ38979865-62EC6932-4214-45A0-B738-E82A0902B5ADQ38988078-C6D12BF1-1170-4216-AE30-958D30DC8CEDQ39041026-770C2728-D99D-45E0-89E6-2613EF828D32Q39071349-06F9DE53-E06B-47E0-9E42-033EE713ED0EQ39100693-CBF39ADE-FB32-432D-BEA8-2F53F4D1F882Q39130451-6FA5D7F7-BA59-47F4-BD87-AB36837224E8Q39149130-27CEC04D-C3A5-4682-A34B-02ABB7D94FCCQ39195507-30F665EA-E3BE-4A23-9759-65A79C9465E0Q39208675-BF5A5D89-5716-431E-9133-3075F0E02D60Q39288497-5FA906FA-92C5-41C3-A1C8-13AA1D77B6AFQ39313794-522C1D80-2922-45B2-A835-A6FED4D27B25Q40496586-4EE017C1-844B-42DA-A1EB-A1D3C653F1F6Q41008660-C169ED55-988B-4146-9858-A1E993AEE917Q41317361-7B501326-6C61-47E6-8AC8-D8A4FE3ECE9D
P2860
MYC regulates the antitumor immune response through CD47 and PD-L1
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
MYC regulates the antitumor immune response through CD47 and PD-L1
@en
type
label
MYC regulates the antitumor immune response through CD47 and PD-L1
@en
prefLabel
MYC regulates the antitumor immune response through CD47 and PD-L1
@en
P2093
P2860
P356
P1433
P1476
MYC regulates the antitumor immune response through CD47 and PD-L1
@en
P2093
Arvin M Gouw
Dean W Felsher
Ines Gütgemann
Kelly N Fitzgerald
Stephanie C Casey
Susanne Walz
Virginie Baylot
P2860
P304
P356
10.1126/SCIENCE.AAC9935
P407
P577
2016-03-10T00:00:00Z